cunmeciclib

Cunmeciclib (also referred to as cummeciclib) is a novel, orally bioavailable small molecule inhibitor of cyclin-dependent kinases 2, 4, and 6 (CDK2/4/6). Developed by Cunmian Pharmaceutical, the agent is primarily being investigated for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer. Unlike selective CDK4/6 inhibitors such as palbociclib, cunmeciclib's broader inhibition profile includes CDK2, which is intended to address a common mechanism of resistance to CDK4/6 blockade—the bypass of the cyclin D-CDK4/6 axis via cyclin E-CDK2 activation. Clinical development is currently focused on Phase II trials in China, evaluating cunmeciclib both as a monotherapy and in combination with endocrine therapies (e.g., fulvestrant) for patients who have previously progressed on standard-of-care CDK4/6 inhibitors.

Other names

cummeciclib存美西利